Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an announcement.
RemeGen Co., Ltd. reported a sharp improvement in its preliminary 2025 financial results, with total operating revenue rising 89.36% year on year to RMB3.25 billion and a swing from a significant loss to a net profit attributable to owners of the parent of RMB708.52 million. The company also turned profitable on a core basis after deducting non-recurring items, strengthened its balance sheet with total assets up 31.65% and owners’ equity up 81.40%, and warned that these figures are unaudited and subject to final confirmation in its forthcoming annual report.
The turnaround in earnings, reflected in a positive basic earnings per share of RMB1.29 and a weighted average return on net assets of 24.88%, suggests a marked recovery in operating performance compared with the previous year’s deep losses. This improvement, if confirmed in audited results, would enhance RemeGen’s financial resilience, potentially bolster investor confidence, and may strengthen its position in the competitive biopharmaceutical sector, though the company has cautioned investors to remain mindful of related investment risks.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$82.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China and listed in Hong Kong. It focuses on developing and commercializing innovative therapies, operating within the broader healthcare and life sciences industry and targeting markets for advanced medical treatments.
Average Trading Volume: 3,822,352
Technical Sentiment Signal: Buy
Current Market Cap: HK$55.89B
Learn more about 9995 stock on TipRanks’ Stock Analysis page.